01 · Fourteen questions
Free base and acetate were voted separately.
Each question asked whether one named form should be placed on the 503A Bulks List. A group summary must preserve both tallies.
Committee votes recordedLast checked · July 25, 2026
The 14 peptide votes are in. Final FDA action is not.
On July 23–24, the Pharmacy Compounding Advisory Committee voted separately on the free-base and acetate forms of seven peptide groups. It recommended inclusion for six groups and against inclusion for emideltide. Those recommendations are advisory; FDA has not made its final 503A Bulks List determinations.
Open the official FDA meeting page ↗FDA’s page links the voting questions, materials, and both archived broadcasts used for this update.
The 90-second version
Three things the vote headlines can blur
02 · Seven recommendations
Six groups in. Emideltide against.
The committee recommended inclusion for both forms of BPC-157, KPV, TB-500, MOTS-c, Epitalon, and Semax. It recommended against both emideltide forms.
03 · One boundary
Recommendation is not final FDA action.
The advisory votes did not approve a drug, place a substance on the final list, verify a product, or create new clinical evidence.
The exact agenda
What FDA says it is evaluating
These uses come directly from the FDA meeting agenda. They are not a list of proven benefits, and they do not describe every reason people currently use or market these compounds.
Day 1 · July 23Four peptide groups
BPC-157
01FDA-evaluated use
Ulcerative colitis
Not a committee review of tendon repair, muscle recovery, or other popular performance claims.
Open status file →KPV
02FDA-evaluated uses
Wound healing and inflammatory conditions
The agenda describes the uses under discussion; it does not establish that KPV is effective for them.
Open status file →TB-500
03FDA-evaluated use
Wound healing
This is not a review of the broader “Wolverine peptide” claims circulating online.
Open status file →MOTS-c
04FDA-evaluated uses
Obesity and osteoporosis
Consideration for compounding is separate from approval as a drug for either condition.
Open status file →Day 2 · July 24Three peptide groups
Emideltide / DSIP
05FDA-evaluated uses
Opioid withdrawal, chronic insomnia, and narcolepsy
“DSIP” is the alternate name readers are more likely to encounter online.
Open status file →Semax
06FDA-evaluated uses
Cerebral ischemia, migraine, and trigeminal neuralgia
The meeting is not a general finding on cognition, focus, or nootropic marketing claims.
Open status file →Epitalon
07FDA-evaluated use
Insomnia
Longevity and “age reversal” claims are not the use listed on the FDA agenda.
Open status file →What the meeting can do
- Give FDA independent expert advice on each substance and evaluated use.
- Produce a public discussion and recommendation that informs FDA’s review.
- Clarify the evidence and concerns FDA believes matter for compounding.
- Create an official record readers can compare with later online claims.
What it cannot do by itself
- Approve any of these substances as an FDA-approved drug.
- Validate uses that are not part of the committee’s stated review.
- Guarantee identity, purity, sterility, or safety of products sold online.
- Turn a non-binding committee recommendation into an immediate final FDA determination.
Recorded results
What happened at the meeting?
FDA’s exact questions and the tally screens in its linked archived broadcasts show 14 separate votes. “Yes” recommended placing the named form on the 503A Bulks List; “No” recommended against it.
8 votes verifiedDay 1 · July 23
Four groups recommended for inclusion
- BPC-157 free base · acetate8–6–1 · 8–6–1
- KPV free base · acetate8–6–1 · 8–6–1
- TB-500 free base · acetate8–6–1 · 8–6–1
- MOTS-c free base · acetate7–5–2 · 7–5–2
Each tally is Yes–No–Abstain. Watch FDA’s linked July 23 archived broadcast ↗
6 votes verifiedDay 2 · July 24
Two groups recommended in; one recommended against
- Emideltide free base · acetate6–7–1 · 6–7–1
- Epitalon free base · acetate7–4–1 · 7–4–1
- Semax free base · acetate8–5–1 · 8–5–1
Emideltide’s No votes outnumbered Yes votes; Epitalon and Semax received Yes majorities. Watch FDA’s linked July 24 archived broadcast ↗
Safety boundary: This page explains a public regulatory meeting. It does not recommend using or avoiding any compound, evaluate an individual product, or provide dosing, sourcing, or treatment advice.
Read the FDA vote decoder →
Read the FDA vote decoder →
Receipts
Official sources
FDA — July 23–24, 2026 Pharmacy Compounding Advisory Committee meeting. Agenda, exact uses evaluated, meeting logistics, materials, and FDA’s explanation that advisory recommendations are non-binding.
FDA — PCAC voting questions. The exact 14 questions, with separate free-base and acetate votes for each peptide group.
FDA — PCAC briefing-document introduction. Explains that FDA is seeking committee advice and does not intend a final determination until committee input is considered and reviews are finalized.
Source status: checked July 25, 2026. Codex verified all 14 tally screens in FDA-linked archived broadcasts, and Claude independently confirmed every tally and exact voting question. Written minutes were not posted on the FDA event page at the time of the primary check; that does not change the recorded advisory tallies. FDA final action remains pending.
If someone may be having a medical problem
Get help first. Report later.
PepCurrent cannot assess symptoms or provide emergency triage.
Call 911 nowIf someone collapses, has a seizure, has trouble breathing, or cannot be awakened.
U.S. Poison ControlCall 1-800-222-1222 or visit Poison.org.
Personal medical questionsContact a licensed clinician who can evaluate the person and their medical history.
Serious product problemAfter appropriate care, patients and clinicians can use FDA MedWatch.
U.S. resources · checked July 16, 2026 · Open the full Help Now page →